Advisory not enough? Why India is weighing mandatory cough syrup warnings for kids
India Considers Mandatory Cough Syrup Warning for Young Children
Theindiapostdaily.com – India is examining a proposal that would require cough syrup bottles to carry a highly visible warning against use in children under four years old. The measure is being considered after concerns that cough and cold medicines continue to be given to infants and toddlers despite earlier government guidance urging doctors and caregivers to avoid them for very young children.
The suggested change would amend Rule 96 of the Drugs Rules, 1945. It would place a red warning prominently on cough syrup packaging and could also require a picture of school-age children, helping distinguish products intended for older children from medicines that might otherwise be used for babies and toddlers.
A proposed red label
The proposed wording is direct and designed to be immediately noticeable on the bottle or pack:
WARNING: Cough syrup should not be used in children below 4 years of age.
Regulators are also considering a visual element showing children of school-going age. The purpose is to reinforce the age limitation without requiring families to rely solely on small-print instructions. A clearer pack design could help communicate that these products are not meant for infants or very young preschool children.
The idea was reviewed at a meeting chaired by the Drugs Controller General of India on Friday, 18 September. It follows technical discussions within the Central Drugs Standard Control Organisation, which oversees drug regulation in the country.
Why the Issue Has Returned to the Forefront
The renewed focus stems from complaints that cough and cold preparations were still being prescribed for children below two years of age. This happened after the Directorate General of Health Services issued an advisory on 3 October 2025 covering the use of such medicines in young children.
That advisory stated that cough and cold medicines should neither be prescribed nor dispensed for children younger than two. It further advised that these medicines are generally not recommended for children below five years. For older children, it stressed the need for clinical assessment, suitable dosing and close monitoring.
The proposed label adopts a four-year threshold, placing a specific warning on the pack itself. This does not erase the broader public-health guidance for children under five. Instead, it would create an additional, product-level reminder that can be seen by doctors, pharmacists and families at the point where a medicine is selected, purchased or administered.
Age-based medical advice can be difficult for caregivers to interpret when a product appears to be marketed broadly as a remedy for coughs or colds. A red warning is intended to make the restriction more obvious, especially in situations where an adult may assume that a children’s formulation is appropriate for any child.
Regulatory Review and Consultation
The matter was taken up by the CDSCO’s Internal Technical Committee on 24 April 2026. The committee proposed consultations with the Indian Council of Medical Research and with relevant stakeholders to assess both the regulatory path and the practical feasibility of revising cough syrup labels and packs.
The ICMR indicated that it was not carrying out work on cough syrup labelling. The regulator has nevertheless moved forward with examining a modification to the labelling rules, with the warning focused on children below four.
Any final rule would matter not only because of the words printed on a package, but because packaging is one of the most immediate safety tools available to the public. Instructions that are prominent, consistent and easy to understand can support the clinical guidance already in place. They may also prompt caregivers to seek medical advice rather than treating a young child’s cough with a syrup intended for a different age group.
Safety Concerns Around Paediatric Syrups
The label proposal comes amid continuing concern over paediatric cough syrup safety. The issue includes questions about whether cough and cold formulations should be used in very young children, as well as the grave risks posed when medicines are contaminated with toxic substances.
Diethylene glycol, commonly known as DEG, and ethylene glycol are among the contaminants linked to serious poisoning incidents. Indian-made paediatric syrups were connected to child deaths in The Gambia in 2022 and in Uzbekistan during 2022 and 2023.
In late 2025, Coldrif cough syrup made by a Chennai-based manufacturer was associated with the deaths of several children in Madhya Pradesh and Rajasthan. Laboratory testing found lethal concentrations of diethylene glycol in the product.
These events underscore why safety measures around paediatric medicines extend beyond one warning label. Product quality, manufacturing controls, prescribing practices, pharmacy dispensing and clear instructions for families all have a role in reducing harm. The present proposal is focused specifically on discouraging cough syrup use in children below four, but it appears within a wider effort to strengthen safeguards around medicines given to children.
What Parents and Caregivers Should Understand
The proposed warning is not yet a final mandatory requirement, but the existing DGHS advisory remains important. Cough and cold medicines should not be prescribed or supplied to children under two, and they are generally not recommended for children younger than five. For older children, their use should follow careful medical evaluation, appropriate dosage and supervision.
A cough can have many causes, and the presence of a cough alone does not establish that a syrup is suitable or necessary for a child. Caregivers should read package information closely and consult a qualified healthcare professional when uncertain about a medicine, a child’s symptoms or the correct dose.
If the proposed amendment is adopted, a red age warning and school-age image could make this decision easier at a glance. The intended message is simple: cough syrup should not be treated as a routine remedy for infants and very young children.
Related Reading
Frequently Asked Questions
What is Advisory not enough Why India is weighing?Advisory not enough Why India is weighing is the main topic of this guide. The article explains the context, practical details, and next steps readers should understand.
Why does Advisory not enough Why India is weighing matter?Advisory not enough Why India is weighing matters because readers are looking for a useful answer, not just a short summary. Good content should match search intent and help them decide what to do next.